Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:ALXO NASDAQ:ATHA NASDAQ:IVVD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$10.55-4.6%$8.54$3.76▼$46.80$64.90M2.7979,581 shs61,168 shsALXOALX Oncology$1.17+2.6%$0.65$0.40▼$2.42$62.65M1.11.70 million shs521,579 shsATHAAthira Pharma$0.39-1.7%$0.38$0.22▼$3.34$15.33M3.0199,772 shs54,581 shsIVVDInvivyd$0.97-1.7%$0.75$0.35▼$2.74$116.90M0.5512.97 million shs3.97 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%+3.43%+41.42%+100.95%-16.80%ALXOALX Oncology0.00%0.00%+125.83%+109.41%-49.57%ATHAAthira Pharma0.00%-2.36%+4.97%+36.30%-87.42%IVVDInvivyd0.00%+87.08%+32.87%+4.62%+14.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics4.2086 of 5 stars3.54.00.04.82.61.70.0ALXOALX Oncology3.0765 of 5 stars3.41.00.00.02.64.21.3ATHAAthira Pharma3.5022 of 5 stars3.05.00.00.03.32.51.3IVVDInvivyd3.9328 of 5 stars3.65.00.00.03.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$50.00373.93% UpsideALXOALX Oncology 2.83Moderate Buy$3.30182.05% UpsideATHAAthira Pharma 2.00Hold$0.5028.67% UpsideIVVDInvivyd 3.25Buy$3.18227.17% UpsideCurrent Analyst Ratings BreakdownLatest ATHA, ALGS, ALXO, and IVVD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.008/25/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.008/18/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.008/15/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $3.006/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/26/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.94M16.47N/AN/A($7.50) per share-1.41ALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/AATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/AIVVDInvivyd$25.38M4.61N/AN/A$0.56 per share1.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$131.21M-$19.79N/AN/AN/A-2,337.24%-22.41%-12.09%11/5/2025 (Estimated)ALXOALX Oncology-$134.85M-$2.20N/AN/AN/AN/A-115.67%-84.82%11/6/2025 (Estimated)ATHAAthira Pharma-$96.94M-$1.55N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)IVVDInvivyd-$169.93M-$0.92N/A8.85N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)Latest ATHA, ALGS, ALXO, and IVVD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/12/2025Q2 2025ALXOALX Oncology-$0.46-$0.49-$0.03-$0.49N/AN/A8/7/2025Q2 2025ATHAAthira Pharma-$0.18-$0.18N/A-$0.18N/AN/A8/6/2025Q2 2025ALGSAligos Therapeutics-$2.35-$1.53+$0.82-$1.53$0.43 million$0.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AALXOALX OncologyN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A6.316.31ALXOALX Oncology0.114.524.52ATHAAthira PharmaN/A10.8110.81IVVDInvivydN/A1.331.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%ALXOALX Oncology97.97%ATHAAthira Pharma57.12%IVVDInvivyd70.36%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics4.80%ALXOALX Oncology21.00%ATHAAthira Pharma19.80%IVVDInvivyd25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.15 million5.86 millionNo DataALXOALX Oncology4053.55 million42.31 millionOptionableATHAAthira Pharma4039.44 million31.63 millionOptionableIVVDInvivyd100120.14 million89.63 millionOptionableATHA, ALGS, ALXO, and IVVD HeadlinesRecent News About These CompaniesInvivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine ActionsAugust 29 at 10:10 AM | seekingalpha.comInvivyd's (IVVD) "Buy" Rating Reaffirmed at HC WainwrightAugust 29 at 8:30 AM | marketbeat.comInvivyd (NASDAQ:IVVD) Earns "Buy" Rating from HC WainwrightAugust 28, 2025 | americanbankingnews.comInvivyd: Covid-19 Prevention Ideal But Future Remains With mAb Development Against RSVAugust 27, 2025 | seekingalpha.comInvivyd (NASDAQ:IVVD) Price Target Cut to $1.00 by Analysts at D. Boral CapitalAugust 27, 2025 | marketbeat.comInvivyd to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comD. Boral Capital Issues Pessimistic Forecast for Invivyd (NASDAQ:IVVD) Stock PriceAugust 27, 2025 | americanbankingnews.comInvivyd rallies amid interest in COVID therapyAugust 26, 2025 | msn.comShares of Invivyd surge on hopes for non-vaccine Covid therapy amid political shiftAugust 26, 2025 | investing.comThis Fidelity stock rockets over 70% on COVID-19 alternative vaccine; Time to buy?August 26, 2025 | finbold.comFInvivyd Raises $53.5 Million in Public OfferingAugust 22, 2025 | tipranks.comInvivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional SharesAugust 22, 2025 | markets.businessinsider.comInvivyd, Inc. Closes Public Offering Raising Approximately $57.5 MillionAugust 22, 2025 | quiverquant.comQInvivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional SharesAugust 22, 2025 | globenewswire.comHC Wainwright Analysts Cut Earnings Estimates for InvivydAugust 22, 2025 | marketbeat.comHC Wainwright Forecasts Invivyd's Q3 Earnings (NASDAQ:IVVD)August 22, 2025 | americanbankingnews.comInsider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 18,512 Shares of StockAugust 21, 2025 | marketbeat.comInsider Selling: Invivyd (NASDAQ:IVVD) CFO Sells 20,013 Shares of StockAugust 21, 2025 | marketbeat.comInvivyd (NASDAQ:IVVD) Insider Timothy Edward Lee Sells 20,013 SharesAugust 21, 2025 | marketbeat.comInsider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 20,013 Shares of StockAugust 21, 2025 | marketbeat.comRobert Allen III Sells 27,420 Shares of Invivyd (NASDAQ:IVVD) StockAugust 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNHBy Ryan Hasson | August 15, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025ATHA, ALGS, ALXO, and IVVD Company DescriptionsAligos Therapeutics NASDAQ:ALGS$10.55 -0.51 (-4.61%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.60 +0.05 (+0.52%) As of 08/29/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.ALX Oncology NASDAQ:ALXO$1.17 +0.03 (+2.63%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.13 -0.04 (-3.42%) As of 08/29/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Athira Pharma NASDAQ:ATHA$0.39 -0.01 (-1.74%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.39 +0.00 (+0.62%) As of 08/29/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Invivyd NASDAQ:IVVD$0.97 -0.02 (-1.72%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.96 -0.01 (-0.82%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
